Accepted for Publication: February 22, 2022.
Published: April 14, 2022. doi:10.1001/jamanetworkopen.2022.7038
Open Access: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2022 Niesen MJM et al. JAMA Network Open.
Corresponding Authors: Venky Soundararajan, PhD, nference, One Main St, East Arcade, Cambridge, MA 02142 (firstname.lastname@example.org); Andrew Badley, Division of Infectious Diseases, Mayo Clinic, 200 First St SW, Rochester, MN 55905 (email@example.com).
Author Contributions: Drs Soundararajan and Badley had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Niesen, Pawlowski, and O’Horo made equal contributions.
Concept and design: Niesen, Pawlowski, O’Horo, Challener, Silvert, Lenehan, Swift, Speicher, Halamka, Venkatakrishnan, Soundararajan, Badley.
Acquisition, analysis, or interpretation of data: Niesen, Pawlowski, O’Horo, Silvert, Donadio, Virk, Gordon, Geyer, Badley.
Drafting of the manuscript: Niesen, Pawlowski, Silvert, Donadio, Venkatakrishnan, Soundararajan.
Critical revision of the manuscript for important intellectual content: Niesen, Pawlowski, O’Horo, Challener, Lenehan, Virk, Swift, Speicher, Gordon, Geyer, Halamka, Soundararajan, Badley.
Statistical analysis: Niesen, Pawlowski, Silvert, Donadio, Gordon.
Administrative, technical, or material support: O’Horo, Silvert, Gordon, Halamka, Badley.
Supervision: Niesen, O’Horo, Venkatakrishnan, Soundararajan, Badley.
Conflict of Interest Disclosures: Drs Niesen and Soundararajan reported being employees of nference, which is collaborating with biopharmaceutical companies on data science initiatives unrelated to this study. Dr Pawlowski reported receiving personal fees from nference outside the submitted work. Dr O’Horo reported receiving grants from nference and Mitre, receiving consulting fees from Bates College, and owning privately purchased stock from Doximity outside the submitted work. Dr Silvert reported receiving personal fees from nference as an employer during the conduct of the study and outside the submitted work. Dr Lenehan reported employment by nference. Dr Virk reported receiving personal fees from Moderna outside the submitted work. Dr Swift reported receiving grants from the Pfizer Healthcare Worker Exposure Response and Outcomes (HEROE) vaccine registry via Duke University outside the submitted work. Dr Badley reported receiving grants from the National Institute of Allergy and Infectious Diseases, Amfar, and Mayo Clinic; consulting fees for AbbVie, Gilead Sciences, Freedom Tunnel, PineTree Therapeutics, Primmune Therapeutics, Immunome, MarPam Pharma, Rion, Symbiosis, and Flambeau Diagnostics; and personal fees from Corvus Pharmaceuticals, Equillium, CSL Behring, Excision BioTherapeutics, ReachMD, PeerVoice, and Medscape; owning equity for scientific advisory work in Zentalis, Rion, and nference; and serving as founder and president of Splissen Therapeutics. No other disclosures were reported.
C , Lenehan
P , Puranik
et al. FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y)
. 2021;2(8):979-992.e8. doi:10.1016/j.medj.2021.06.007
MG , Burgess
JL , Naleway
et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3
SJ , Rowley
EA , Ong
et al; VISION Network. Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance—nine states, June-August 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(37):1291-1293. doi:10.15585/mmwr.mm7037e2
WH , Tenforde
MW , Rhoads
et al; IVY Network. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions–United States, March-August 2021. MMWR Morb Mortal Wkly Rep
. 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1
A , PJ
Lenehan , JC
et al. Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. bioRxiv.
Preprint posted online September 7, 2021. doi:10.1101/2021.09.04.21263115Google Scholar
A , Merzon E, Shäffer AA,
et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. medRxiv.
Preprint posted online August 5, 2021. doi:10.1101/2021.08.03.21261496Google Scholar
R , Lenehan
P , Awasthi
et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (N Y)
. 2021;2(8):965-978.e5. doi:10.1016/j.medj.2021.06.006
M , Ychezkel
M , Guan
et al. Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose. bioRxiv
. Preprint posted online September 22, 2021. doi:10.1101/2021.09.15.21263633Google Scholar
J , Chang
MW , Lee
K , and Toutanova
K. BERT: pre-training of deep bidirectional transformers for language understanding. arXiv.org. Accessed March 8, 2022. https://arxiv.org/abs/1810.04805
T , Shweta
F , Murugadoss
et al. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. Elife
. 2020;9:e58227. doi:10.7554/eLife.58227